Exploring the impact of HIV infection and antiretroviral therapy on placenta morphology
Michael Yampolsky, Oleksandr Shlakhter, Dianna Deng, Smriti Kala, Sharon Walmsley, Kellie E. Murphy, Mark H. Yudin, Jay MacGillivray, Mona Loutfy, Caroline Dunk, Lena Serghides
Abstract
Women living with HIV experience more adverse birth outcomes; the mechanisms are not fully understood. We examined placenta morphology and associations with birth outcomes in a Canadian cohort of women living with HIV (HIV+) on antiretroviral therapy (ART) from conception and HIV-uninfected (HIV−) women. Term placentas from 94 women (40 HIV−, 54 HIV+) were studied. Trimmed placenta weight was collected. Placenta digital photos were used to compute morphometric parameters. Regression models investigated associations between log-transformed placenta parameters and birth outcomes. We observed a trend towards lower placenta weight and smaller placenta area in the HIV+ group, both of which were significantly associated with small for gestational age births. HIV+ serostatus was associated with 6-fold (95%CI 2–20) greater odds of having placenta area in the lowest quartile (<236 cm2). Cord marginality (distance from the edge) was significantly lower in the HIV+ group (p = 0.004), with 35% of placenta having an abnormal (marginal or velamentous) cord insertion vs. 12.5% in the HIV− group (p = 0.01). Velamentous cord insertion was seen in 13% of placentas in the HIV+ vs. 0% in HIV− group (p = 0.02). A significant correlation between cord marginality and placenta thickness was observed in the HIV− group, with a more marginal cord being associated with a thicker placenta. This correlation was not observed in the HIV+ group. HIV+ placentas exposed to protease inhibitors were significantly less circular compared to the HIV− group (p = 0.03). Our data suggest that HIV/ART exposure affects placenta morphology and is associated with higher rates of abnormal cord insertion.